基蛋生物(603387.SH):2名董事和股東減持期過半 累計減持22.48萬股
格隆匯12月1日丨基蛋生物(603387.SH)公佈,截止本公告披露日,公司董事孔婷婷於2020年9月2日至2020年9月25日通過集合競價交易方式累計減持了5.68萬股,約佔公司總股本的0.0218%。
公司股東王勇於2020年8月31日至2020年11月16日通過集合競價交易方式累計減持了16.8萬股,約佔公司總股本的0.0645%。
上述董事和股東本次減持時間過半,董事孔婷婷本次計劃尚餘9.9997萬股未完成。股東王勇本次計劃尚餘45.9332萬股未完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.